Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

With these results, they also estimate that if everyone in this broader population of potentially eligible patients took GLP-1s, it could result in 34,000 fewer heart attacks and strokes each year ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

The GLP-1 segment is a very important class of drugs ... mainly due to its solid pipeline potential, particularly its obesity drugs. The stock is also trading above its 200-day moving average ...